20272 ⎘
Medicinal preparations containing organic active ingredients; Compounds containing heavy metals Platinum compounds
Pharmaceutical combination for the treatment and/or chemosensibilization of refractory tumors to anticancer drugs
#902NOVEL ANTITUMOR AGENT COMPRISING COMBINATION OF THREE AGENTS
#903Nanoparticle Formulations in Biomarker Detection
#904Medicament, method, and drug delivery device for treatment of ovarian cancer
#905METHODS AND COMPOSITIONS FOR TREATING RECURRENT CANCER
#906Cancer therapy
#907Method of Treating Cancer with DLL4 Antagonist and Chemotherapeutic Agent
#908COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAEPTUC AGENTS, AND METHODS OF USE
#909Pharmaceutical compositions for treating cancer
#910Ligand-targeted molecules and methods thereof
#911Combined anticancer drug sensitivity-determining marker
#912ASSOCIATION BETWEEN N-HYDROXY-4-BENZAMIDE AND FOLFOX
#913GLIOMA TREATMENT
#914Human papilloma virus as predictor of cancer prognosis
#915Compositions including triciribine and one or more platinum compounds and methods of use thereof
#916Procaspase 3 activation by combination therapy
#917Inhibition of dynamin related protein 1 to promote cell death
#918Poxviral oncolytic vectors
#919Therapeutic curcumin derivatives
#920Anti-IGF antibodies
#921Pharmaceutical compositions comprising an antibody which binds the human anti-mullerian hormone receptor type II
#922MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS
#923Use of 2-deoxy-D-glucose to sensitize cancer cells to an agent that activates the extrinsic apoptotic pathway
#924Functionalised silicon nanoparticles
#925NOVEL LIPOSOME COMPOSITIONS
#926BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS
#927METHODS FOR TREATING CANCERS USING ORAL FORMULATIONS OF CYTIDINE ANALOGS
#928Treating prostate, ovarian, or breast cancer with a whole, leech saliva extract
#929COMPOSITIONS AND METHODS FOR TREATMENT OF METASTATIC CANCER
#930Platinum compound having amino or alkylamino-containing succinic acid derivatives as leaving group, preparation method thereof, and use thereof
#931Anti-PD-L1 antibodies and uses thereof
#932Charge triggering of self-organized nanoparticles
#933Mycophenolic acid analogues as anti-tumor chemosensitizing agents
#934Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
#935Endoglin antibodies
#936METHODS AND COMPOSITIONS FOR THE TREATMENT OF OVARIAN CANCER
#937Low-Dose Combination Chemotherapy
#938Method for preparing nanoparticles based on functional amphiphilic molecules or macromolecules, and the use thereof
#939Novel Analogs of Curcumin and Methods of Use
#940Combination therapy for ovarian cancer
#941Monoclonal antibodies for tumor treatment
#942Method for treatment of mesothelioma
#943Combinations of AKT inhibitor compounds and vemurafenib, and methods of use
#944LIPOSOME OXALIPLATIN COMPOSITIONS FOR CANCER THERAPY
#945Combinations of AKT inhibitor compounds and abiraterone, and methods of use
#946Method of treating colorectal cancer
#947Combination Therapy for Treating Proliferative Diseases
#948Method of treating cancer
#949Method for isolating a chemotherapeutic agent resistant cancer cell with stem cell properties
#950Combinations of AKT inhibitor compounds and erlotinib, and methods of use
#951NANOPARTICLE ARSENIC-PLATINUM COMPOSITIONS
#952Methods and monitoring of treatment with a DLL4 antagonist
#953METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID IN COMBINATION THERAPY
#954Pharmaceutical combination comprising a CIP2A silencing agent for use in the treatment of a hyperproliferative disorder, preferably one with impaired p53 function
#955METHOD OF REDUCING MULTI-DRUG RESISTANCE USING INOSITOL TRIPYROPHOSPHATE
#956INDIBULIN THERAPY
#957Targeted Conjugates Encapsulated in Particles and Formulations Thereof
#958Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
#959Cancer treatments
#960ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF OVARIAN CANCER
#961TREATMENT WITH ANTI-VEGF ANTIBODIES
#962COMBINATION THERAPY METHODS FOR TREATING PROLIFERATIVE DISEASES
#963Chroman derivatives, medicaments and use in therapy
#964COMBINATION THERAPY METHODS FOR TREATING PROLIFERATIVE DISEASES
#965Use of amisulpride as an anti-emetic
#966Platinum compounds for treating cell proliferative diseases, preparation method and use thereof
#967Anti-tumor drug, medicament, composition, and use thereof
#968Therapeutic combinations for use in neoplasia
#969Selective androgen receptor modulator for treating hormone-related conditions
#970USE OF A FOOD COMPOSITION IN THE TREATMENT AND/OR PREVENTION OF NEUROPATHIC PAIN INDUCED BY AN ANTICANCER AGENT
#971COMBINED PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TUMORS
#972Method for the treatment of cancer
#973Antibodies to interleukin-6
#974Marker for determination of sensitivity to anticancer agent
#975Compositions and methods for localized drug delivery through mammary papillae
#976Uses of an immunomodulatory protein (GMI) from
#977Combinations and modes of administration of therapeutic agents and combination therapy
#978Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
#979METHODS OF TREATING BLADDER CANCER
#980Human papilloma virus as predictor of cancer prognosis
#981Transfection of Mesothelium Body Cavity Lining with Gene Agents Followed by Chemotharapy to Treat Cancer of Organs in the Body Cavity
#982Oxidized cellulose miczrospheres including visualization agents
#983Pharmaceutical composition
#984Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent
#985TREATMENTS FOR CELLULAR PROLIFERATIVE DISORDERS AND IDENTIFICATION THEREOF
#986Methods of treating cancer
#987Marker for determination of sensitivity to triplet combination anti-cancer agent
#988Cancer Treatment Method
#989HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME
#990Stabilized Angiopoietin-2 Antibodies And Uses Thereof
#991Combination Therapy With Organic Arsenicals
#992Lipid raft, caveolin protein, and caveolar function modulation compounds and associated synthetic and therapeutic methods
#993Pharmaceutical composition and method of treating a microbial infection with sulcotidil
#994ABROGATING PROINFLAMMATORY CYTOKINE PRODUCTION DURING ONCOLYTIC REOVIRUS THERAPY
#995Oligonucleotide analogues incorporating 5-aza-cytosine therein
#996ANTI-IGF ANTIBODIES
#997Combinations and modes of administration of therapeutic agents and combination therapy
#998Methods and compositions for malic enzyme 2 (ME2) as a target for cancer therapy
#999COMBINATIONS AND MODES OF ADMINISTRATION OF THERAPEUTIC AGENTS AND COMBINATION THERAPY
#1000TREATMENT WITH ANTI-VEGF ANTIBODIES
#1001Use of armillaridin for treating cancer
#1002Substituted triazolopyridines
#1003Cancer Treatment Method
#1004Methods of treating cancer with a thieno[3,2-C]pyridine
#1005Methods of treating cancer using a combination of an immunomodulatory compound and an artemisinin or a derivative thereof
#1006Mutated humanized 12G4 antibodies and the fragments thereof against the human anti-Mullerian hormone receptor type II
#1007HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME
#1008Method for preparing novel processed ginseng or an extract thereof, the usually minute ginsenoside content of which is increased
#1009Method for treatment of advanced solid tumors
#1010TRIAZOLOPYRIDINE DERIVATIVES
#1011Compounds useful as inhibitors of ATR kinase
#1012Compounds useful as inhibitors of ATR kinase
#1013Compounds useful as inhibitors of ATR kinase
#1014Combinational liposome compositions for cancer therapy
#1015Methods for treating cancers using oral formulations of cytidine analogs
#1016CHOLESTANOL DERIVATIVE FOR COMBINED USE
#1017Methods and materials related to ovarian cancer
#1018Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor
#1019Humanized anti-EGFL7 antibodies and methods using same
#1020Use of riluzole for treating or preventing the adverse effects of antineoplastic agents
#1021COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT
#1022Prevention of and Recovery from Drug-Induced Ototoxicity
#1023DELIVERY SYSTEM FOR SPECIFICALLY TARGETING CANCER CELLS AND METHOD OF USE THEREOF
#1024Compositions including triciribine and one or more platinum compounds and methods of use thereof
#1025Bis[thiohydrazide amide] compounds for treating leukemia
#1026Wnt antagonists and methods of treatment and screening
#1027TREATMENT WITH ANTI-VEGF ANTIBODIES
#1028Use of amisulpride as an anti-emetic
#1029Use of amisulpride as an anti-emetic
#1030Chemotherapeutic methods and compositions
#1031Anti-cancer agent delivery vehicles capable of improved loading
#1032PARABEN COMPOSITIONS
#1033Compositions useful for reducing nephrotoxicity and methods of use thereof
#1034EXOSOMAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE
#1035Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
#1036Local treatment of neurofibromas
#1037METHOD FOR THE TREATMENT OF CANCER
#1038Combination Therapy With Organic Arsenicals
#1039TREATMENT OF LUNG CANCER
#1040Endoglin antibodies
#1041Method and Device for Restoring Spinal Disk Functions
#1042Drug, drug guidance system, magnetic detection system, and drug design method
#1043Thiazole Compounds, and Compositions and Methods Using Same
#1044TREATMENT OF BREAST CANCER WITH IODONITROBENZAMIDES IN COMBINATION WITH ANTI-TUMOR AGENTS
#1045Use of Quinazoline Derivative ZD6474 Combined With Platinum Compounds and Optionally Ionising Radiation in the Treatment of Diseases Associated With Angiogenesis and/or Increased Vascular Permeability
#1046FGFR1 extracellular domain combination therapies for lung cancer
#1047METHOD FOR CARRYING THERAPEUTIC SUBSTANCES INTO CELLS
#1048EPIDITHIODIOXOPIPRAZINES AND USES THEREOF IN TREATING CANCER
#1049TREATMENT OF ONCOLOGICAL DISEASES
#1050Nanoscale platinum compounds and methods of use thereof
#1051HYDROGELS USED TO DELIVER MEDICAMENTS TO THE EYE FOR THE TREATMENT OF POSTERIOR SEGMENT DISEASES
#1052Combinations and modes of administration of therapeutic agents and combination therapy
#1053MEDICAL USE OF SPLA2 HYDROLYSABLE LIPOSOMES
#1054Chroman derivatives, medicaments and use in therapy
#1055Soluble Nanoparticles as Delivery Systems for Prodrugs
#1056COMBINATION THERAPY FOR CANCER COMPRISING A PLATINUM-BASED ANTINEOPLASTIC AGENT AND A BIOCOMPATIBLE ELECTRON DONOR
#1057Method for prediction of therapeutic effect of chemotherapy employing expression level of dihydropyrimidine dehydrogenase gene as measure
#1058Method of therapy
#1059Process for preparing trichloroammineplatinate salt and the products obtained therein
#1060Crystal forms of kinase inhibitors
#1061COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER
#1062PENTAMIDINE COMBINATIONS FOR TREATING CANCER
#1063Methods of treating cancer
#1064Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent
#1065Treatment of cancer with specific RXR agonists
#1066Compositions comprising a radiosensitizer and an anti-cancer agent and methods of uses thereof
#1067USE OF ALKANOYL L-CARNITINE IN COMBINATION WITH CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF NEOPLASMS
#1068Method for predicting therapeutic efficacy of chemotherapy on non-small-cell lung cancer
#1069ANTI-TUMOR AGENT CONTAINING TEGAFUR-GIMERACIL-OTERACIL POTASSIUM COMBINATION DRUG AND OXALIPLATIN
#1070Methods for treating cancer and other pathological proliferating disorders by inhibiting mitosis using pyrrolo[2,3-]pyrimidines
#1071COMBINATION OF A TLR3 LIGAND AND A CHEMOTHERAPY AGENT WHICH ACTS ON THE INTRINSIC "APOPTOSIS" PATHWAY IN THE TREATMENT OF CANCER
#1072METHODS OF TREATING CANCER HAVING AN ABERRANT EGFR OR KRAS GENOTYPE
#1073METHODS FOR SUPPRESSING AN IMMUNE RESPONSE OR TREATING A PROLIFERATIVE DISORDER
#1074Interior functionalized hyperbranched dendron-conjugated nanoparticles and uses thereof
#1075PHD2 inhibition for blood vessel normalization, and uses thereof
#1076CHOLESTANOL DERIVATIVE FOR COMBINED USE
#1077CHOLESTANOL DERIVATIVE FOR COMBINED USE
#1078Chroman derivatives, medicaments and use in therapy
#1079METHOD OF REDUCING MULTI-DRUG RESISTANCE USING INOSITOL TRIPYROPHOSPHATE
#1080TARGETED ACTIVE AGENT DELIVERY SYSTEM BASED ON CALCIUM PHOSPHATE NANOPARTICLES
#1081Methods, compositions and articles of manufacture for contributing to the treatment of cancers
#1082DOWN-REGULATION OF COLD SHOCK PROTEINS FOR CANCER TREATMENT
#1083SNS-595 and methods of using the same
#1084Methods and compositions for contributing to the treatment of cancers
#1085Wnt Antagonists and Methods of Treatment and Screening
#1086CANCER TREATMENT METHOD
#1087Modified vaccinia virus strains for use in diagnostic and therapeutic methods
#1088COMBINATION CANCER TREATMENT
#1089Combination therapy for the treatment of cancer
#1090Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
#1091SNS-595 AND METHODS OF USING THE SAME
#1092Platinum (IV) complexes for use in dual mode pharmaceutical therapy
#1093Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
#1094Anti-angiogenesis therapy for the treatment of ovarian cancer
#1095METHODS AND KITS TO PREDICT PROGNOSTIC AND THERAPEUTIC OUTCOME IN SMALL CELL LUNG CANCER
#1096Use of cilastatin to reduce nephrotatoxicity of various compounds
#1097COMBINATION COMPRISING AN IRON CHELATOR AND AN ANTI-NEOPLASTIC AGENT AND USE THEREOF
#1098CONCENTRATED OXALIPLATIN SOLUTION AND ITS METHOD OF PREPARATION
#1099Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
#1100Antitumor agent, kit and method of treating cancer
#1101Combination Therapy for Treating Proliferative Diseases
#1102HUMANIZED ANTI-ERBB2 ANTIBODIES AND TREATMENT WITH ANTI-ERBB2 ANTIBODIES
#1103TREATMENT WITH ANTI-VEGF ANTIBODIES
#1104COMBINATORIAL THERAPIES FOR THE TREATMENT OF NEOPLASIAS USING THE OPIOID GROWTH FACTOR RECEPTOR
#1105THERAPEUTIC COMBINATION COMPRISING AN AURORA KINASE INHIBITOR AND AN ANTINEOPLASTIC AGENT
#1106Monoclonal antibodies for tumor treatment
#1107Extracellular matrix compositions for the treatment of cancer
#1108CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTS (E.G. SERM OR ALKYLATING AGENTS)
#1109Liposome compositions
#1110Endoglin antibodies
#1111Combination Therapy with an Antitumor Alkaloid
#1112Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
#1113Cryo-medical injection device and method of use
#1114Method for Preparing Nanoparticles Based on Functional Amphiphilic Molecules or Macromolecules, and the Use Thereof
#1115Cancer chemotherapy compositions comprising PI3K pathway modulators and triptolide
#1116Stabilized angiopoietin-2 antibodies and uses thereof
#1117Methods of Reducing Methotrexate Nephrotoxicity
#1118Methods for Reducing Cisplatin Nephrotoxicity
#1119METHODS AND COMPOSITIONS FOR TREATING CANCER
#1120NANOPARTICLE ARSENIC-PLATINUM COMPOSITIONS
#1121Antitumoral Treatments
#1122Method for the treatment of cancer
#1123COMBINATION OF A RETINOID AND A PLATINUM ANTICANCER AGENT
#1124Agent for enhancing anti-tumor effect comprising oxaliplatin liposome preparation, and anti-tumor agent comprising the liposome preparation
#1125Method of treating cancer with DLL4 antagonist and chemotherapeutic agent
#1126AXL antibodies
#1127Method for determination of sensitivity to anti-cancer agent
#1128Combination therapy with organic arsenicals
#1129NOVEL COMPOSITION FOR TREATING THE SIDE EFFECTS OF ANTICANCER TREATMENTS
#1130ORAL FORMULATIONS FOR PICOPLATIN
#1131Medicament for the treatment of cancer of the pancreas
#1132Pharmaceutical composition or combination drug
#1133Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-OXO-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy
#1134Therapeutic Cancer Treatments
#1135Quinone derivatives, pharmaceutical compositions, and uses thereof
#1136ENHANCEMENT OF ANTIBODY-CYTOKINE FUSION PROTEIN MEDIATED IMMUNE RESPONSES BY COMBINED TREATMENT WITH IMMUNOCYTOKINE UPTAKE ENHANCING AGENTS
#1137Humanized anti-EGFL7 antibodies and methods using same
#1138Benzoquinone derivative E3330 in combination with chemotherapeutic agents for the treatment of cancer and angiogenesis
#1139FORMULATIONS OF ORGANO-PLATINIC COMPOUNDS IN THE PRESENCE OF ASSOCIATIVE POLYMERS, PRODUCTS THUS OBTAINED AND USES THEREOF
#1140STABLE OXALIPLATIN COMPOSITION FOR PARENTERAL ADMINISTRATION
#1141Methods of inhibiting cell growth and methods of enhancing radiation responses
#1142TREATMENT WITH ANTI-VEGF ANTIBODIES
#1143Therapeutic Cancer Treatments
#1144Use of Quinazoline Derivative ZD6474 Combined With Platinum Compounds and Optionally Ionising Radiation in the Treatment of Diseases Associated With Angiogenesis and/or Increased Vascular Permeability
#1145Methods and compositions for treating recurrent cancer
#1146Oligonucleotide analogues incorporating 5-aza-cytosine therein
#1147Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha
#1148Chemotherapeutic methods and compositions
#1149Pulsatile Dosing of Gossypol for Treatment of Disease
#1150Oxaliplatin active substance with a very low content of oxalic acid
#1151COMPOSITIONS INCLUDING TRICIRIBINE AND ONE OR MORE PLATINUM COMPOUNDS AND METHODS OF USE THEREOF
#1152Anti-tumor drug, medicament, composition, and use thereof
#1153Anti-IGF antibodies
#1154Production of an Oxaliplatin Mixture and a Container and a Container Set for Said Mixture
#1155Treatment of lung cancer
#1156USE OF A DNA DAMAGING AGENT AND A LIGAND FOR THE TREATMENT OF CANCER
#1157Extracellular matrix compositions for the treatment of cancer
#1158Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use Thereof
#1159NANOPARTICLES OF PACLITAXEL AND ALBUMIN IN COMBINATION WITH BEVACIZUMAB AGAINST CANCER
#1160DISCONTINUOUS METHODS OF TREATING CANCER
#1161COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT
#1162OXALIPLATIN PHARMACEUTICAL COMPOSITION WITH ALCOHOLIC SUGAR-BASED BUFFER
#1163Compositions useful for reducing nephrotoxicity and methods of use thereof
#1164Method of treating cancer with an RPN2 gene expression inhibitor
#1165ANTI-TUMOR COMPOSITION
#1166CANCER TREATMENT METHOD
#1167ACID CONTAINING OXALIPLATIN FORMULATIONS
#1168Cholestanol derivative for combined use
#1169Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
#1170Methods for promoting protection and regeneration of bone marrow using CXCL9 and anti-CXCL9 antibodies
#1171OXALIPLATIN FORMULATIONS
#1172Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
#1173Combinations of therapeutic agents for treating cancer
#1174Pharmaceutical composition for oral administration
#1175Antimicrobial Composition
#1176TREATMENT OF BREAST CANCER WITH A PARP INHIBITOR ALONE OR IN COMBINATION WITH ANTI-TUMOR AGENTS
#1177Treatment of pain using satraplatin
#1178Combination Comprising an Iron Chelator and an Anti-Neoplastic Agent and Use Thereof
#1179Second line treatment of metastatic hormone refractory prostate cancer using satraplatin
#1180Thiazole compounds, and compositions and methods using same
#1181Drug, drug guidance system, magnetic detection system, and drug design method
#1182Combinations and modes of administration of therapeutic agents and combination therapy
#1183Use of picoplatin to treat colorectal cancer
#1184TREATMENT WITH ANTI-VEGF ANTIBODIES
#1185Compositions and methods of use of compounds to increase cancer patient survival time
#1186KINESIN INHIBITORS
#1187PHARMACEUTICAL COMPOSITION FOR ADMINISTRATION BY INJECTION
#1188Treatment with anti-VEGF Antibodies
#1189Pharmaceutical Preparation of Aqueous Solution Containing Platinum Complex
#1190THERAPEUTIC CANCER TREATMENTS
#1191PHARMACEUTICAL COMPOSITION FOR INJECTIONAL PARTICULARLY TARGETED LOCAL ADMINISTRATION
#1192Pulsatile Dosing of Gossypol for Treatment of Disease
#1193Liposome Preparation
#1194Modified vaccinia virus strains for use in diagnostic and therapeutic methods
#1195Methods, compositions and articles of manufacture for contributing to the treatment of cancers
#1196Combination anticancer agents
#1197Methods and compositions for the treatment of cancer using benzopyrone-type PARP inhibitors
#1198ANTI-TUMORAL, ANTIBACTERIAL AND ANTIVIRAL PHARMACEUTICAL COMPOSITION (VARIANTS)
#1199Intestinal absorptive anti-tumor agent
#1200Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents